PP_1170x120_10-25-21

Dr. Roger Perlmutter

Merck to acquire OncoImmune

Merck to acquire OncoImmune

KENILWORTH, N.J. — Merck and OncoImmune, a privately-held, clinical-stage biopharmaceutical company,  announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments

Merck to acquire VelosBio

Merck to acquire VelosBio

KENILWORTH, N.J. — Merck and VelosBio Inc. announced Thursday that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer

Merck and ISB team to define molecular mechanisms of SARS-CoV-2 infection

Merck and ISB team to define molecular mechanisms of SARS-CoV-2 infection

KENILWORTH, N.J. — Merck and the Institute for Systems Biology (ISB), announced on Monday a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of

Merck to buy ArQule, advancing leadership in oncology

Merck to buy ArQule, advancing leadership in oncology

KENILWORTH, N.J. — Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development